
Research team improves safety of LGMD2A gene therapy
Limb-girdle muscular dystrophy type 2A (LGMD2A or LGMDR1) is a neuromuscular disorder hat causes progressive muscle weakness and has no cure. The...

SciRhom targets autoimmunity switch
Backed by a €7m seed financing from the High-Tech Gruenderfonds (HTGF), HSS and private investors, SciRhom targets iRhom2, a regulator of tumor...

New malaria lead kills 99.9% of pathogens
The researchers built on the fact, that Plasmodium is highly dependent on external supply and metabolisation of vitamin B 5 (pantothenamide). They...

Healx Ltd raises $56m in Series B financing
The financing was led by Atomico and joined by Intel Capital, Global Brain and btov Partners as new investors. Existing investors from a US$10m...

Creoptix AG closes CHF8m financing round
The financing round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation as well as existing private investors....

Abcam buys Expedeon’s immunology business
“This purchase price is equivalent to twice Expedeon’s current market capitalisation or excess of 9-times 2018 annual group revenue,” the company...

ImCheck Therapeutics SAS raises €48m
The €48m financing was co-led by Pfizer Ventures, the venture capital arm of Pfizer Inc., and Bpifrance, with the new investors Wellington Partners,...